^
RAS mutation
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
RAS mutation
AML
venetoclax
Sensitive: C2 – Inclusion Criteria
RAS mutation
Multiple Myeloma
selinexor
Sensitive: C3 – Early Trials
RAS mutation
CRC
sorafenib
Sensitive: C3 – Early Trials
RAS mutation
CRC
EGFR inhibitor
Sensitive: C3 – Early Trials
RAS mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive: C3 – Early Trials
RAS mutation
CRC
pembrolizumab + selinexor
Sensitive: C3 – Early Trials
RAS mutation
Thyroid Gland Carcinoma
trametinib
Sensitive: C3 – Early Trials
RAS mutation
CRC
cetuximab
Resistant: C3 – Early Trials
RAS mutation
CRC
bevacizumab
Resistant: C3 – Early Trials
RAS mutation
Rectal Cancer
SOXIRI
Sensitive: C3 – Early Trials
RAS mutation
Rectal Cancer
FOLFOXIRI
Sensitive: C3 – Early Trials
RAS mutation
AML
mTOR inhibitor
Resistant: D – Preclinical